Renal Cell Carcinoma Diagnostics
Advertisement
ACSS2 Inhibition as a Therapeutic Strategy in ccRCC: Impacts on HIF-2α, Metabolism, and Tumor Growth
The group discusses how blocking ACSS2 may affect immune cells in the tumor microenvironment. 
Drs. Beckermann, Rathmell, and Bacigalupa highlight the potential of ACSS2 as a therapeutic target in kidney cancer.
Researchers evaluated the tissue samples of 126 treatment-naïve patients collected from a multicenter database.
Dr. Simpa Salami's research into a 15-gene prognostic signature for predicting ccRCC risk is discussed in this interview.
ACSS2 inhibition led to lowered chromatin accessibility, HIF-2α expression, and stability.
Rana McKay, MD, provides commentary on the safety of 89Zr-girentuximab PET/CT for treating clear cell renal cell carcinoma.
The signature has been initially validated to improve ccRCC risk stratification and provide better treatment allocation.
The use of 89Zr PET/CT and subsequent surgery in patients treated with it demonstrated low radiation exposure levels.
Drs. Xu and Joyce explain the rationale behind recent research on plasma KIM-1, its significance as a biomarker, and more.
Kidney injury molecule-1 is a transmembrane protein that can serve as a urinary indicator of acute renal tubular injury.
Drs. Joyce and Psutka consider patient counseling for adjuvant RCC therapy, and biomarkers and imaging before treatment.
Drs. Joyce and Khanna examine the utility of a deep learning algorithm for automated renal volume calculation.
Drs. Joyce and Pierorazio weigh appropriate surveillance versus primary intervention for clinical T1a kidney tumors.
A new study by an international research team has identified new susceptibility regions associated with RCC development risk.
We spoke with several researchers involved in exploring the clinical utility of liquid biopsy for genitourinary cancers.
Dr. Wei helped uncover genetic, transcriptional, and immune differences in TFE3-rearranged RCC versus papillary, ccRCC.
A new study on the prognostic value of perinephric fat, renal sinus fat, and renal vein invasion in patients with pT3a RCC.
Targeted gene panel testing can serve as an option for patients if syndromic features are present.
Researchers sought to identify the frequency of germline mutations in patients 46 years or younger.
Researchers evaluated biomarkers to determine their prognostic potential for determining treatment modality for ccRCC.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.